345 related articles for article (PubMed ID: 12051548)
21. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
22. Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats.
Ma YF; Jee WS; Ke HZ; Lin BY; Liang XG; Li M; Yamamoto N
J Bone Miner Res; 1995 Mar; 10(3):496-505. PubMed ID: 7785472
[TBL] [Abstract][Full Text] [Related]
23. Parathyroid hormone (1-34) increased total body bone mass in aged female rats.
Simmons HA; Pirie CM; Thompson DD; Ke HZ
J Pharmacol Exp Ther; 1998 Jul; 286(1):341-4. PubMed ID: 9655878
[TBL] [Abstract][Full Text] [Related]
24. CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.
Liu F; Lee SK; Adams DJ; Gronowicz GA; Kream BE
Bone; 2007 Apr; 40(4):1135-43. PubMed ID: 17275432
[TBL] [Abstract][Full Text] [Related]
25. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
Takeuchi Y
Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
[TBL] [Abstract][Full Text] [Related]
26. ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats.
Neerup TS; Stahlhut M; Petersen JS; Daugaard JR; Jensen JE; Peng Z; Morko J; Thorkildsen C
Bone; 2011 Jun; 48(6):1319-27. PubMed ID: 21376152
[TBL] [Abstract][Full Text] [Related]
27. Effects of parathyroid hormone (1-34) on tibia in an adult rat model for chronic alcohol abuse.
Sibonga JD; Iwaniec UT; Shogren KL; Rosen CJ; Turner RT
Bone; 2007 Apr; 40(4):1013-20. PubMed ID: 17204460
[TBL] [Abstract][Full Text] [Related]
28. Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats.
Rowshan HH; Parham MA; Baur DA; McEntee RD; Cauley E; Carriere DT; Wood JC; Demsar WJ; Pizarro JM
J Oral Maxillofac Surg; 2010 Feb; 68(2):260-7. PubMed ID: 20116693
[TBL] [Abstract][Full Text] [Related]
29. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
[TBL] [Abstract][Full Text] [Related]
30. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.
Frolik CA; Black EC; Cain RL; Satterwhite JH; Brown-Augsburger PL; Sato M; Hock JM
Bone; 2003 Sep; 33(3):372-9. PubMed ID: 13678779
[TBL] [Abstract][Full Text] [Related]
31. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
[TBL] [Abstract][Full Text] [Related]
32. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats.
Turner RT; Evans GL; Lotinun S; Lapke PD; Iwaniec UT; Morey-Holton E
J Bone Miner Res; 2007 Jan; 22(1):64-71. PubMed ID: 17042715
[TBL] [Abstract][Full Text] [Related]
33. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
[TBL] [Abstract][Full Text] [Related]
35. Impacts of the N-terminal fragment analog of human parathyroid hormone on structure, composition and biomechanics of bone.
Chunxiao W; Yu Z; Wentao L; Jingjing L; Jiahui Y; Qingmei C
Eur J Pharm Sci; 2012 Dec; 47(5):926-33. PubMed ID: 23046835
[TBL] [Abstract][Full Text] [Related]
36. Sequential treatment with intermittent low-dose human parathyroid hormone (1-34) and bisphosphonate enhances large-size skeletal reconstruction by vascularized bone transplantation.
Hashimoto T; Shigetomi M; Ohno T; Matsunaga T; Muramatsu K; Tanaka H; Sugiyama T; Taguchi T
Calcif Tissue Int; 2007 Sep; 81(3):232-9. PubMed ID: 17674071
[TBL] [Abstract][Full Text] [Related]
37. Systemic bone formation with weekly PTH administration in ovariectomized rats.
Gittens SA; Wohl GR; Zernicke RF; Matyas JR; Morley P; Uludag H
J Pharm Pharm Sci; 2004 Jan; 7(1):27-37. PubMed ID: 15144732
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
39. Proliferative bone lesions in rats fed a diet containing glucocorticoid for up to two years.
Zwicker GM; Eyster RC
Toxicol Pathol; 1996; 24(2):246-50. PubMed ID: 8992615
[TBL] [Abstract][Full Text] [Related]
40. Serum proteome profiles identifies parathyroid hormone physiologic response.
Prahalad AK; Hickey RJ; Huang J; Hoelz DJ; Dobrolecki L; Murthy S; Winata T; Hock JM
Proteomics; 2006 Jun; 6(12):3482-93. PubMed ID: 16705755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
